$5.47 Billion is the total value of RA Capital Management's 70 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 40.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $911,991,000 | +25.5% | 5,909,742 | +20.2% | 16.68% | +17.8% |
| FMTX | FORMA THERAPEUTICS HLDGS INC | $449,141,000 | +7.2% | 9,011,651 | 0.0% | 8.22% | +0.6% | |
| CCXI | CHEMOCENTRYX INC | $264,515,000 | -4.8% | 4,826,910 | 0.0% | 4.84% | -10.6% | |
| PCVX | Sell | VAXCYTE INC | $260,915,000 | +50.4% | 5,283,818 | -3.7% | 4.77% | +41.1% |
| TGTX | Sell | TG THERAPEUTICS INC | $236,180,000 | -5.2% | 8,825,849 | -31.0% | 4.32% | -11.0% |
| NKTX | New | NKARTA INC | $168,490,000 | – | 5,605,129 | +100.0% | 3.08% | – |
| AXSM | AXSOME THERAPEUTICS INC | $145,003,000 | -13.4% | 2,035,132 | 0.0% | 2.65% | -18.7% | |
| PHAT | PHATHOM PHARMACEUTICALS INC | $140,263,000 | +11.4% | 3,825,008 | 0.0% | 2.57% | +4.6% | |
| MCRB | New | SERES THERAPEUTICS INC | $134,473,000 | – | 4,750,000 | +100.0% | 2.46% | – |
| NVAX | Sell | NOVAVAX INC | $129,869,000 | -67.3% | 1,198,602 | -74.8% | 2.38% | -69.3% |
| ETNB | Buy | 89BIO INC | $121,531,000 | +92.9% | 4,736,214 | +49.8% | 2.22% | +81.0% |
| RYTM | Sell | RHYTHM PHARMACEUTICALS INC | $111,393,000 | -4.1% | 5,140,408 | -1.3% | 2.04% | -10.0% |
| MGNX | Sell | MACROGENICS INC | $110,212,000 | -13.9% | 4,375,217 | -4.6% | 2.02% | -19.2% |
| EIDX | Buy | EIDOS THERAPEUTICS INC | $109,310,000 | +6.0% | 2,163,271 | +0.0% | 2.00% | -0.5% |
| ITOS | New | ITEOS THERAPEUTICS INC | $108,974,000 | – | 4,417,258 | +100.0% | 1.99% | – |
| ZGNX | Buy | ZOGENIX INC | $98,407,000 | -0.9% | 5,488,424 | +49.2% | 1.80% | -7.0% |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $96,932,000 | -40.5% | 9,410,860 | +20.6% | 1.77% | -44.1% |
| ADAP | Sell | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $90,410,000 | -30.8% | 11,329,581 | -13.2% | 1.65% | -35.0% |
| TRILLIUM THERAPEUTICS INC | $87,572,000 | +75.6% | 6,162,694 | 0.0% | 1.60% | +64.8% | ||
| ARVN | ARVINAS INC | $86,717,000 | -29.6% | 3,672,872 | 0.0% | 1.59% | -33.9% | |
| RTRX | RETROPHIN INC | $85,575,000 | -9.6% | 4,635,687 | 0.0% | 1.56% | -15.1% | |
| KALA | KALA PHARMACEUTICALS INC | $81,560,000 | -28.6% | 10,874,613 | 0.0% | 1.49% | -33.0% | |
| BDTX | BLACK DIAMOND THERAPEUTICS INC | $78,293,000 | -28.3% | 2,589,904 | 0.0% | 1.43% | -32.7% | |
| LEGN | Sell | LEGEND BIOTECH CORPsponsored ads | $74,344,000 | -29.6% | 2,408,292 | -3.0% | 1.36% | -33.9% |
| IGMS | IGM BIOSCIENCES INC | $72,535,000 | +1.1% | 982,723 | 0.0% | 1.33% | -5.1% | |
| KROS | KEROS THERAPEUTICS INC | $72,319,000 | +2.8% | 1,875,000 | 0.0% | 1.32% | -3.4% | |
| VXRT | New | VAXART INC | $71,893,000 | – | 10,810,937 | +100.0% | 1.32% | – |
| WVE | WAVE LIFE SCIENCES LTD | $66,012,000 | -18.4% | 7,775,207 | 0.0% | 1.21% | -23.5% | |
| PMVP | New | PMV PHARMACEUTICALS INC | $60,714,000 | – | 1,710,265 | +100.0% | 1.11% | – |
| DYN | New | DYNE THERAPEUTICS INC | $56,634,000 | – | 2,805,045 | +100.0% | 1.04% | – |
| INZY | New | INOZYME PHARMA INC | $52,676,000 | – | 2,003,653 | +100.0% | 0.96% | – |
| GERN | GERON CORP | $52,420,000 | -20.2% | 30,126,299 | 0.0% | 0.96% | -25.1% | |
| AKUS | AKOUOS INC | $52,172,000 | +1.6% | 2,281,249 | 0.0% | 0.95% | -4.6% | |
| ORTX | Buy | ORCHARD THERAPEUTICS PLCads | $50,616,000 | +10.8% | 12,315,213 | +18.4% | 0.93% | +4.0% |
| CRDF | New | CARDIFF ONCOLOGY INC | $46,685,000 | – | 3,290,000 | +100.0% | 0.85% | – |
| RLAY | New | RELAY THERAPEUTICS INC | $42,590,000 | – | 1,000,000 | +100.0% | 0.78% | – |
| INBX | New | INHIBRX INC | $38,322,000 | – | 2,129,003 | +100.0% | 0.70% | – |
| ALEC | Sell | ALECTOR INC | $38,124,000 | -62.2% | 3,618,748 | -12.3% | 0.70% | -64.5% |
| CRNX | CRINETICS PHARMACEUTICALS INC | $36,491,000 | -10.6% | 2,328,698 | 0.0% | 0.67% | -16.1% | |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $34,140,000 | -3.1% | 1,165,184 | 0.0% | 0.62% | -9.2% | |
| ARDX | ARDELYX INC | $32,870,000 | -24.1% | 6,260,904 | 0.0% | 0.60% | -28.8% | |
| VRNA | New | VERONA PHARMA PLCsponsored ads | $31,824,000 | – | 5,100,000 | +100.0% | 0.58% | – |
| RLMD | Sell | RELMADA THERAPEUTICS INC | $29,392,000 | -22.9% | 781,290 | -8.3% | 0.54% | -27.6% |
| SCPH | SCPHARMACEUTICALS INC | $26,217,000 | +1.2% | 3,518,998 | 0.0% | 0.48% | -5.0% | |
| IMGN | New | IMMUNOGEN INC | $25,346,000 | – | 7,040,485 | +100.0% | 0.46% | – |
| LRMR | LARIMAR THERAPEUTICS INC | $22,985,000 | +18.1% | 1,515,151 | 0.0% | 0.42% | +10.8% | |
| STRO | Buy | SUTRO BIOPHARMA INC | $21,288,000 | +42.9% | 2,118,212 | +10.3% | 0.39% | +34.1% |
| OCUL | OCULAR THERAPEUTIX INC | $20,755,000 | -8.6% | 2,727,272 | 0.0% | 0.38% | -14.2% | |
| PAND | New | PANDION THERAPEUTICS INC | $20,284,000 | – | 1,770,023 | +100.0% | 0.37% | – |
| PRVL | Sell | PREVAIL THERAPEUTICS INC | $19,500,000 | -47.5% | 1,915,568 | -23.2% | 0.36% | -50.7% |
| CNCE | CONCERT PHARMACEUTICALS INC | $18,250,000 | -1.3% | 1,858,474 | 0.0% | 0.33% | -7.2% | |
| STSA | SATSUMA PHARMACEUTICALS INC | $18,212,000 | -86.5% | 4,681,858 | 0.0% | 0.33% | -87.3% | |
| MIST | New | MILESTONE PHARMACEUTICALS INC | $17,706,000 | – | 2,418,798 | +100.0% | 0.32% | – |
| SNDX | SYNDAX PHARMACEUTICALS INC | $15,100,000 | -0.4% | 1,023,067 | 0.0% | 0.28% | -6.4% | |
| BCTG | New | BCTG ACQUISITION CORP | $12,950,000 | – | 1,250,000 | +100.0% | 0.24% | – |
| RPTX | REPARE THERAPEUTICS INC | $12,585,000 | -0.8% | 409,000 | 0.0% | 0.23% | -6.9% | |
| FSDC | New | FS DEV CORP | $11,198,000 | – | 1,000,000 | +100.0% | 0.20% | – |
| ARYA | New | ARYA SCIENCES ACQUISITION CO | $10,815,000 | – | 1,000,000 | +100.0% | 0.20% | – |
| VSTM | Sell | VERASTEM INC | $9,760,000 | -37.8% | 8,066,171 | -11.6% | 0.18% | -41.5% |
| SLDB | SOLID BIOSCIENCES INC | $9,279,000 | -30.7% | 4,571,164 | 0.0% | 0.17% | -34.9% | |
| LYRA | LYRA THERAPEUTICS INC | $9,252,000 | 0.0% | 815,849 | 0.0% | 0.17% | -6.1% | |
| ARYBU | ARYA SCIENCES ACQUISITION CORPunit 06/09/2027 | $7,700,000 | -5.1% | 700,000 | 0.0% | 0.14% | -10.8% | |
| GRTX | GALERA THERAPEUTICS INC | $7,459,000 | +26.6% | 825,118 | 0.0% | 0.14% | +18.3% | |
| HSAQ | New | HEALTH SCIENCES ACQ CORP 2 | $6,875,000 | – | 625,000 | +100.0% | 0.13% | – |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $5,236,000 | -65.0% | 353,072 | -69.3% | 0.10% | -67.0% |
| IMRA | Sell | IMARA INC | $5,080,000 | -77.8% | 249,739 | -69.9% | 0.09% | -79.2% |
| PASG | PASSAGE BIO INC | $4,230,000 | -52.0% | 322,630 | 0.0% | 0.08% | -55.2% | |
| XFOR | X4 PHARMACEUTICALS INC | $3,788,000 | -27.3% | 559,494 | 0.0% | 0.07% | -32.4% | |
| EPIX | Sell | ESSA PHARMA INC | $3,246,000 | -38.4% | 470,428 | -44.6% | 0.06% | -42.7% |
| OVID | OVID THERAPEUTICS INC | $1,636,000 | -22.1% | 285,000 | 0.0% | 0.03% | -26.8% | |
| SELB | Exit | SELECTA BIOSCIENCES INC | $0 | – | -95,000 | -100.0% | -0.01% | – |
| INSM | Exit | INSMED INC | $0 | – | -87,405 | -100.0% | -0.05% | – |
| AVDL | Exit | AVADEL PHARMACEUTICALS PLCsponsored adr | $0 | – | -3,126,131 | -100.0% | -0.49% | – |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -1,119,963 | -100.0% | -0.52% | – |
| MNTA | Exit | MOMENTA PHARMACEUTICALS INC | $0 | – | -2,531,445 | -100.0% | -1.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
About RA Capital Management
RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.
The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.
RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.
Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.
Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ASCENDIS PHARMA A/S - ADR | 35 | Q3 2023 | 25.5% |
| WAVE LIFE SCIENCES PTE LTD | 32 | Q3 2023 | 26.3% |
| TG THERAPEUTICS INC | 30 | Q4 2021 | 6.3% |
| ZOGENIX INC | 26 | Q4 2021 | 9.5% |
| BIOCRYST PHARMACEUTICALS | 23 | Q1 2019 | 9.2% |
| DICERNA PHARMACEUTICALS INC | 23 | Q3 2019 | 5.8% |
| RHYTHM PHARMACEUTICALS INC | 22 | Q3 2023 | 4.4% |
| ACHILLION PHARMACEUTICALS INC | 19 | Q4 2017 | 17.2% |
| KALA PHARMACEUTICALS INC | 19 | Q1 2022 | 4.4% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 6.8% |
View RA Capital Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | September 22, 2023 | 6,940,000 | 6.2% |
| BELLUS Health Inc.Sold out | August 14, 2023 | 0 | 0.0% |
| Kinnate Biopharma Inc.Sold out | August 14, 2023 | 0 | 0.0% |
| Vor Biopharma Inc. | August 11, 2023 | 22,780,343 | 33.7% |
| DICE Therapeutics, Inc.Sold out | August 09, 2023 | 0 | 0.0% |
| Acumen Pharmaceuticals, Inc. | July 25, 2023 | 14,981,618 | 25.9% |
| Talaris Therapeutics, Inc. | July 06, 2023 | 2,333,175 | 5.5% |
| Aerovate Therapeutics, Inc. | June 27, 2023 | 8,293,148 | 30.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | June 12, 2023 | 0 | 0.0% |
| ARYA Sciences Acquisition Corp VSold out | May 15, 2023 | 0 | 0.0% |
View RA Capital Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-25 |
| 4 | 2024-04-15 |
| 4 | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-12 |
| SC 13G | 2024-04-12 |
| SC 13D/A | 2024-04-11 |
| SC 13G | 2024-04-11 |
| 4 | 2024-04-04 |
| SC 13G | 2024-04-04 |
View RA Capital Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.